'Breaker track bwelbb04hla' diaporamas de présentation

Sasisopin Kiertiburanakul , MD, MHS , Surakameth Mahasirimongkol , MD, MSc, PhD,

Late Breaker Track B WELBB04 HLA-B*35:05 and CCHCR1 Screening Reduces Nevirapine -associated Cutaneous Adverse Reactions in Thailand: A Prospective Multicenter Randomized Controlled Trial (NCT 00986063). Sasisopin Kiertiburanakul , MD, MHS , Surakameth Mahasirimongkol , MD, MSc, PhD,

441 views • 28 slides